# Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

> **NCT05187884** · PHASE2 · COMPLETED · sponsor: **St Vincent's Hospital, Sydney** · enrollment: 15 (actual)

## Conditions studied

- Ocular Melanoma

## Interventions

- **DRUG:** Darovasertib

## Key facts

- **NCT ID:** NCT05187884
- **Lead sponsor:** St Vincent's Hospital, Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-03
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05187884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05187884, "Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05187884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*